MX2020013905A - Metodos para el tratamiento del cancer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecificos. - Google Patents
Metodos para el tratamiento del cancer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecificos.Info
- Publication number
- MX2020013905A MX2020013905A MX2020013905A MX2020013905A MX2020013905A MX 2020013905 A MX2020013905 A MX 2020013905A MX 2020013905 A MX2020013905 A MX 2020013905A MX 2020013905 A MX2020013905 A MX 2020013905A MX 2020013905 A MX2020013905 A MX 2020013905A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- methods
- cd3xmuc16
- treating cancer
- bispecific
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000007269 CA-125 Antigen Human genes 0.000 abstract 2
- 108010008629 CA-125 Antigen Proteins 0.000 abstract 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los métodos de la presente invención comprenden administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de un anticuerpo o fragmento de fijación al antígeno de este que se une específicamente al receptor de muerte programada 1 (PD-1) en combinación con una cantidad terapéuticamente eficaz de un anticuerpo biespecífico que se une específicamente a Mucina 16 (MUC16) y CD3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688251P | 2018-06-21 | 2018-06-21 | |
| PCT/US2019/038163 WO2019246356A1 (en) | 2018-06-21 | 2019-06-20 | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013905A true MX2020013905A (es) | 2021-03-09 |
Family
ID=67254001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013905A MX2020013905A (es) | 2018-06-21 | 2019-06-20 | Metodos para el tratamiento del cancer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecificos. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11254752B2 (es) |
| EP (2) | EP3810281B1 (es) |
| JP (1) | JP7403480B2 (es) |
| KR (1) | KR20210023981A (es) |
| CN (1) | CN112312970B (es) |
| AU (1) | AU2019290170A1 (es) |
| BR (1) | BR112020025476A2 (es) |
| CA (1) | CA3103887A1 (es) |
| CL (1) | CL2020003256A1 (es) |
| DK (1) | DK3810281T3 (es) |
| EA (1) | EA202190088A1 (es) |
| ES (1) | ES2984972T3 (es) |
| FI (1) | FI3810281T3 (es) |
| HU (1) | HUE067985T2 (es) |
| IL (1) | IL279251A (es) |
| MA (2) | MA52962B1 (es) |
| MX (1) | MX2020013905A (es) |
| PH (1) | PH12020552115A1 (es) |
| PL (1) | PL3810281T3 (es) |
| PT (1) | PT3810281T (es) |
| RS (1) | RS65886B1 (es) |
| SG (1) | SG11202012137UA (es) |
| TW (1) | TW202504917A (es) |
| WO (1) | WO2019246356A1 (es) |
| ZA (1) | ZA202007599B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ES2846748T3 (es) | 2015-03-30 | 2021-07-29 | Regeneron Pharma | Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma |
| HRP20250234T1 (hr) | 2018-08-31 | 2025-04-11 | Regeneron Pharmaceuticals, Inc. | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| WO2022197907A2 (en) * | 2021-03-18 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors |
| WO2023033022A1 (ja) | 2021-08-31 | 2023-03-09 | 日本メジフィジックス株式会社 | 脱グリコシル化抗体の放射性複合体、及び、放射性医薬 |
| CN118475618A (zh) * | 2021-11-24 | 2024-08-09 | 瑞泽恩制药公司 | 用双特异性抗CD3xMUC16抗体和抗CTLA-4抗体治疗癌症的方法 |
| US20230312718A1 (en) * | 2022-01-07 | 2023-10-05 | Regeneron Pharmaceuticals, Inc | Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies |
| TW202334234A (zh) | 2022-01-10 | 2023-09-01 | 大陸商南京維立志博生物科技有限公司 | 一種抗體及其用途 |
| EP4494655A1 (en) * | 2022-03-16 | 2025-01-22 | Daiichi Sankyo Company, Limited | Combination of multi-specific molecule and immune checkpoint inhibitor |
| JP2025512377A (ja) | 2022-04-11 | 2025-04-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ユニバーサルな腫瘍細胞殺傷のための組成物及び方法 |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| MXPA02001877A (es) | 1999-08-23 | 2002-08-20 | Dana Farber Cancer Inst Inc | Pd-1, un receptor para b7-4, y usos del mismo. |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| CN103059138B (zh) | 2005-05-09 | 2015-10-28 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| MX342623B (es) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US20180355038A1 (en) | 2015-09-23 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| FI3394103T3 (fi) * | 2015-12-22 | 2023-08-30 | Regeneron Pharma | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| SMT202200359T1 (it) | 2016-09-23 | 2022-11-18 | Regeneron Pharma | Anticorpi anti-muc16 (mucina 16) |
| CA3040504A1 (en) * | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Il15/il15ra heterodimeric fc-fusion proteins |
| BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
-
2019
- 2019-06-19 TW TW113114645A patent/TW202504917A/zh unknown
- 2019-06-20 MA MA52962A patent/MA52962B1/fr unknown
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en active IP Right Grant
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
- 2019-06-20 HU HUE19739472A patent/HUE067985T2/hu unknown
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 KR KR1020217000649A patent/KR20210023981A/ko active Pending
- 2019-06-20 MA MA71708A patent/MA71708A/fr unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 CN CN201980040564.9A patent/CN112312970B/zh active Active
- 2019-06-20 AU AU2019290170A patent/AU2019290170A1/en active Pending
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 ES ES19739472T patent/ES2984972T3/es active Active
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 PL PL19739472.9T patent/PL3810281T3/pl unknown
- 2019-06-20 EP EP24176671.6A patent/EP4424712A3/en active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
-
2020
- 2020-12-07 IL IL279251A patent/IL279251A/en unknown
- 2020-12-07 ZA ZA2020/07599A patent/ZA202007599B/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2984972T3 (es) | 2024-10-31 |
| TW202504917A (zh) | 2025-02-01 |
| EP4424712A3 (en) | 2024-11-13 |
| MA52962A (fr) | 2021-04-28 |
| PH12020552115A1 (en) | 2021-08-02 |
| SG11202012137UA (en) | 2021-01-28 |
| TW202005985A (zh) | 2020-02-01 |
| KR20210023981A (ko) | 2021-03-04 |
| CN112312970A (zh) | 2021-02-02 |
| ZA202007599B (en) | 2025-02-26 |
| CL2020003256A1 (es) | 2021-04-30 |
| EP3810281B1 (en) | 2024-07-24 |
| IL279251A (en) | 2021-01-31 |
| PL3810281T3 (pl) | 2024-11-04 |
| JP2021528423A (ja) | 2021-10-21 |
| EA202190088A1 (ru) | 2021-03-22 |
| BR112020025476A2 (pt) | 2021-03-16 |
| HUE067985T2 (hu) | 2024-12-28 |
| US11254752B2 (en) | 2022-02-22 |
| CN112312970B (zh) | 2025-05-23 |
| EP4424712A2 (en) | 2024-09-04 |
| FI3810281T3 (fi) | 2024-08-14 |
| MA71708A (fr) | 2025-05-30 |
| RS65886B1 (sr) | 2024-09-30 |
| EP3810281A1 (en) | 2021-04-28 |
| CA3103887A1 (en) | 2019-12-26 |
| US20190389966A1 (en) | 2019-12-26 |
| PT3810281T (pt) | 2024-08-02 |
| JP7403480B2 (ja) | 2023-12-22 |
| DK3810281T3 (da) | 2024-08-19 |
| AU2019290170A1 (en) | 2021-01-07 |
| MA52962B1 (fr) | 2024-10-31 |
| WO2019246356A1 (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020552115A1 (en) | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies | |
| BR112018012801A2 (pt) | combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 para tratar o câncer | |
| MX2018007756A (es) | Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda. | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| PH12019502275A1 (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| MX2019013033A (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| ZA201905051B (en) | Anti-pd-1 antibodies for treatment of lung cancer | |
| MX2018008347A (es) | Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3. | |
| MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| MX2020002301A (es) | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
| CA3242629A1 (en) | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies | |
| MX2021005686A (es) | Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer. | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MX2024006187A (es) | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. | |
| MX2024011298A (es) | Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1 | |
| MX2024014019A (es) | Métodos para el tratamiento del cáncer de próstata resistente a la castración metastásico con anticuerpos biespecíficos anti-psma x anti-anticuerpos de cd3 solos o en combinación con anticuerpos anti-pd-1 |